2nd Test

Question 1

XenMatrix’s ________ structure allows for early remodeling and is ___ times more than it’s largest competitor.

Answer 1

Collagen, 3

Question 2

Is Roth’s “18 month Phasix study” Clinical or pre-clinical?

Answer 2

Clinical

Question 3

The recurrence rate of the Pomahac follow-up study was _____ with a follow-up of _____ months and a average size defect of _______.

Answer 3

7.9
40.1
435cm

Question 4

Match the # of patients to the study

74 Patients—————Iannitti- “Innitti’s Early Clinical outcomes..,”
55 Patients—————Byrnes/Croston- “Repair of High Risk”
40 Patients—————Pomahac- “Abdominal Wall Recon”
25 Patients—————Novitsky- “Multicenter, prospective all-comers”

Answer 4

.

Question 5

Buell completed the 1st ever________(product name) published clinical data with a recurrence rate of_______. This study included #_____ patients and showed a cost advantage of _______.

Answer 5

Phasix
6.5%
73
$9,570.07

Question 6

Pre-clinical studies demonstrated that the repair strength of XenMatrix AB is more than _____ times stronger than native porcine abdominal wall at 12 weeks.

Answer 6

3

Question 7

In vivo model testing showed bacterial clearance of MRSA at 7 days as
_____% for XenMatrix AB & _______% for Strattice.

Answer 7

100

0

Question 8

How would you use the load transfer graph when talking to a surgeon?

Answer 8

After the 52 week follow up the mesh once it’s remolded it is 3X stronger than the normal mesh strength.

The mesh loses strength over time as the abdominal wall increases.

Question 9

Byrnes/Croston- “Repair of high risk…” was the study on:

Answer 9

Xen Matrix

Question 10

Buell’s “Intial experience with…” was a study on:

Answer 10

Phasix

Question 11

Iannitti’s “Early clinical outcomes…” was a study on:

Answer 11

Xen AB